NZYM B Novozymes A/S Class B

Interim report Q1 2025

Interim report Q1 2025

Strong start to the year and confirmed full-year outlook

Ester Baiget, President & CEO:  “We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. Growth was driven by strong innovation especially in emerging markets, and with a continued broad pull for our solutions in developed markets. Synergies are materializing as expected and we are confirming the full-year outlook. We continue to see solid demand across the business, and our regional presence and resilient global setup enable us to respond with agility in these dynamic times”.

  • Strong organic sales growth of 11% including ~1pp from price. All sales areas with double-digit organic sales growth. Emerging markets organic sales growth at 15% and developed markets at 9%.
  • Adjusted EBITDA margin at 38.3%, up by 310bps.
  • Adjusted net profit increased by 27%.
  • NIBD/EBITDA at 1.1x.
  • Announcement on February 11 to acquire dsm-firmenich’s part of the feed enzyme alliance at a EUR 1.5bn cash consideration, expected to close in the second quarter.
  • Andrew Taylor announced on April 22 as new EVP Food & Beverages, joining the company no later than September 1, 2025.
  • 2025 outlook maintained: 5-8% organic sales growth (6-9% excluding the exit from certain countries) and an adjusted EBITDA margin between 37-38% despite current currency headwinds.



Please read the full announcement in PDF

Attachment



EN
08/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Novonesis delivered a strong Q1 with 11% organic growth and confirms f...

Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook. The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter. Ester Baiget, President & CEO, say...

 PRESS RELEASE

Interim report Q1 2025

Interim report Q1 2025 Strong start to the year and confirmed full-year outlook Ester Baiget, President & CEO:  “We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. Growth was driven by strong innovation especially in emerging markets, and with a continued broad pull for our solutions in developed markets. Synergies are materializing as expected and we are confirming the full-year outlook. We continue to see solid demand across the business, and our regional presence and resilient global setup enable us to respond with...

 PRESS RELEASE

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Please read the announcement in PDF Attachment

 PRESS RELEASE

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Please read the announcement in PDF Attachment

 PRESS RELEASE

Andrew Taylor joins Novonesis’ Executive Leadership Team

Andrew Taylor joins Novonesis’ Executive Leadership Team Andrew Taylor will assume the role as EVP of Food & Beverage Biosolutions at Novonesis. Please read the full announcement in PDF. Attachment

ResearchPool Subscriptions

Get the most out of your insights

Get in touch